ALT5 Sigma Plans Division of Fintech, Biotech Arms

MT Newswires Live

2024/10/02

ALT5 Sigma (ALTS) said Wednesday it plans to separate into two independent public companies, one focused on fintech and the other on biotechnology.

The company said the fintech business will retain the ALT5 name, while the biotech arm will operate as Alyea Therapeutics, creating non-opioid pain management therapies.

The company's board has approved the split, ALT5 added.

ALT5 also said it has named The Ohio Pain Clinic's chairman and founder Amol Soin as the chief executive officer of Alyea Therapeutics.

Shares of ALT5 were up 3.3% in recent early Wednesday trading.

Price: 1.89, Change: +0.06, Percent Change: +3.28

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎国际,美股交易,港股交易,交易美股,股票信息,股价,美股行情,美股打新,港股打新,IPO打新,购买美股,全球投资","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2472526625"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2472526625\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2472526625?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-10-02 21:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2472526625","market":"hk","top_or_hot":-1,"title":"ALT5 Sigma Plans Division of Fintech, Biotech Arms","media":"MT Newswires Live","content":"<html><body><p> ALT5 Sigma (ALTS) said Wednesday it plans to separate into two independent public companies, one focused on fintech and the other on biotechnology.</p><p>The company said the fintech business will retain the ALT5 name, while the biotech arm will operate as Alyea <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, creating non-opioid pain management therapies.</p><p>The company's board has approved the split, ALT5 added.</p><p>ALT5 also said it has named The Ohio Pain Clinic's chairman and founder Amol Soin as the chief executive officer of Alyea Therapeutics.</p><p>Shares of ALT5 were up 3.3% in recent early Wednesday trading.</p><p>Price: 1.89, Change: +0.06, Percent Change: +3.28</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ALT5 Sigma Plans Division of Fintech, Biotech Arms</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nALT5 Sigma Plans Division of Fintech, Biotech Arms\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-10-02 21:48</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> ALT5 Sigma (ALTS) said Wednesday it plans to separate into two independent public companies, one focused on fintech and the other on biotechnology.</p><p>The company said the fintech business will retain the ALT5 name, while the biotech arm will operate as Alyea <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a>, creating non-opioid pain management therapies.</p><p>The company's board has approved the split, ALT5 added.</p><p>ALT5 also said it has named The Ohio Pain Clinic's chairman and founder Amol Soin as the chief executive officer of Alyea Therapeutics.</p><p>Shares of ALT5 were up 3.3% in recent early Wednesday trading.</p><p>Price: 1.89, Change: +0.06, Percent Change: +3.28</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FTVI","symbol_name":"Fintech Acquisition Corp VI","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2472526625","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2472526625","pubTimestamp":1727876935,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"ALT5 Sigma (ALTS) said Wednesday it plans to separate into two independent public companies, one focused on fintech and the other on biotechnology.The company said the fintech business will retain the","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FTVI":"Fintech Acquisition Corp VI","BK4007":"制药","ALTS":"PROSHARES MORNINGSTAR ALTERNATIVES SOLUTION ETF"},"translate_title":"ALT5 Sigma计划设立金融科技部门、生物技术部门","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FTVI":1,"ALTS":0.9},"content_text":"ALT5 Sigma (ALTS) said Wednesday it plans to separate into two independent public companies, one focused on fintech and the other on biotechnology.The company said the fintech business will retain the ALT5 name, while the biotech arm will operate as Alyea Therapeutics, creating non-opioid pain management therapies.The company's board has approved the split, ALT5 added.ALT5 also said it has named The Ohio Pain Clinic's chairman and founder Amol Soin as the chief executive officer of Alyea Therapeutics.Shares of ALT5 were up 3.3% in recent early Wednesday trading.Price: 1.89, Change: +0.06, Percent Change: +3.28","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}